For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnantmares, as an aid in the reduction of respiratory disease caused by equine influenza virus types A2 North American and A2 Eurasian.
Vaccination and proper management are
the keys to a successful prevention
program. Your veterinarian can design a
specific vaccination protocol and provide
you with management strategies designed
to minimize exposure of your horse in high
risk situations. A good management
program must be built around an effective
Administration and Dosage: Shake well before use. Using aseptic technique, inoculate horses
intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a
different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal
Precautions: Store at 35-45°F (2-7°C). Protect from freezing. Do not vaccinate within 21 days. Anaphylactoid reactions may occur following use. Antidote: Epinephrine.
This product has been tested under laboratory conditions and shown to meet all Federal standards for
safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be
affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual
idiosyncrasies, or impaired immunological competency. These factors should
be considered by the user when evaluating product performance or freedom
Preservatives: Gentamicin and thimerosal.